查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863554

心臟就地檢驗市場按產品類型、最終用戶、分銷管道、檢測模式、技術和應用分類－2025-2032年全球預測

Cardiac Point of Care Testing Market by Product Type, End User, Distribution Channel, Test Mode, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，心臟就地檢驗市場規模將達到 259.5 億美元，複合年成長率為 13.55%。

關鍵市場統計數據
基準年 2024 93.8億美元
預計年份：2025年 106.6億美元
預測年份 2032 259.5億美元
複合年成長率 (%) 13.55%

本文闡述了加速診斷應對力和分散式心臟檢測為何正在重塑臨床路徑和市場優先事項的策略框架。

心臟就地檢驗已成為急慢性心血管疾病治療路徑中的關鍵轉折點，它使臨床醫生能夠在患者家門口快速做出決策，並將診斷範圍擴展到傳統檢查室之外。近期技術進步縮短了檢測時間，提高了分析靈敏度，而醫療保健趨勢正在推動急診診所、門診中心、居家醫療機構和醫院檢查室對分散式檢查的需求。這些趨勢正在重塑臨床醫生對胸痛進行分診、監測心臟衰竭和評估心血管風險的方式，快速的診斷結果將帶來更及時的干涉措施和更精簡的診療路徑。

生物標記靈敏度的提高、設備的微型化以及醫療服務改革正在共同重塑心臟診斷和臨床工作流程。

在技​​術創新、臨床實踐發展和醫療服務改革的共同推動下，心臟就地檢驗領域正經歷變革性的轉變。高靈敏度的生物標記檢測延長了心肌損傷和心臟衰竭的診斷窗口期，促使人們重新評估分診通訊協定，並縮短急診和門診患者的治療時間。同時，生物感測器小型化和檢測化學技術的進步使得在中心檢查室之外也能獲得可靠的定量結果，從而支持轉向分散式、以患者為中心的診斷模式。

檢驗2025年關稅調整對營運和商業的影響，以及這些調整將如何影響供應鏈韌性、採購和定價策略。

2025年生效的累積關稅為心臟就地檢驗生態系統帶來了新的商業性和營運複雜性。關稅導致進口零件、試劑原料和成品診斷設備的成本壓力，迫使製造商和經銷商重新評估籌資策略和供應鏈結構。為了降低貿易政策波動帶來的風險，一些機構正在加快供應商多元化，包括優先選擇低關稅地區的合作夥伴，並尋求近岸外包方案。這些策略因應措施對採購產生直接影響，並可能影響各通路的產品定價和利潤率趨勢。

透過深入的細分分析，將產品類型、最終用戶需求、通路、測試模式、技術和臨床應用連結起來，從而解鎖有針對性的策略重點。

細分市場分析揭示了臨床需求、技術契合度和分銷動態之間的交集，從而在心臟就地檢驗市場中創造了差異化的機會。按產品類型分類，市場涵蓋腦鈉肽（BNP）、C反應蛋白、肌酸激酶MB（CK MB）、肌紅蛋白和肌鈣蛋白，並進一步區分了BNP與N端腦鈉肽前體（NT-proBNP）、C反應蛋白與高敏和標準方法，以及肌鈣蛋白從肌鈣蛋白I到肌鈣蛋白T。終端使用者細分揭示了門診中心、急診診所、居家醫療服務和醫院檢查室在採用模式上的差異，表明每個機構都有其獨特的工作流程要求、人員能力和採購行為。分銷管道包括醫院藥房、線上管道（包括B2B入口網站和D2C服務）以及零售藥房，每個管道都有不同的利潤率預期和客戶參與模式。

醫療保健基礎設施、監管要求和製造生態系統方面的區域差異會影響產品的採用路徑和策略性市場推廣方式。

區域趨勢對即時心臟檢測 (POCT) 的應用路徑、監管要求和供應鏈決策有重大影響。在美洲，急診對快速分流的需求以及日益成長的居家醫療舉措（這些計劃傾向於使用攜帶式診斷設備）正在推動臨床應用，但公立和私立醫療系統之間的採購週期和報銷機制存在顯著差異。歐洲、中東和非洲地區呈現多元化的格局，監管協調工作與市場分散並存，導致設備和檢測套組的應用路徑各不相同。雖然集中式系統在某些地區仍然佔據主導地位，但其他市場正在快速採用分散式檢查，這通常受到公共衛生優先事項和投資能力的影響。亞太地區擁有先進的城市醫療保健系統和完善的檢測網路，而新興經濟體正在迅速擴展基層醫療基礎設施。該地區的製造能力和供應商生態系統在全球供應鏈中也發揮核心作用，影響採購決策和定價趨勢。

競爭與合作趨勢凸顯了平台現有企業和創新者如何利用分銷、連接和證據生成來確保永續的市場地位。

就地檢驗領域的競爭格局既有成熟的診斷設備製造商，也有專注於超靈敏生物標記、以用戶為中心的設備設計和整合數位生態系統等細分領域的敏捷型新興企業。大型平台公司往往利用其廣泛的分銷網路、完善的監管體系和跨產品組合的協同效應來擴大應用規模，而新興參與企業則專注於平台靈活性、低成本製造或能夠實現快速迭代開發的新型生物感測器技術。

為製造商、經銷商和醫療系統制定切實可行的高優先級行動指南，以加速產品推廣應用、增強韌性並與臨床優先事項保持一致。

產業領導者若想加速推廣應用並建立穩健的業務，應優先考慮兼顧臨床可靠性、供應鏈靈活性和終端用戶體驗的實用策略。首先，應投資於臨床證據，以證明就地檢驗與病患診療路徑的可衡量改善（例如，縮短診斷時間、避免不必要的住院治療）之間的關聯，並確保這些證據涵蓋各種終端使用者環境，包括門診中心、急診診所、居家醫療機構和醫院檢查室。其次，應透過組裝替代採購管道、盡可能將組裝環節外包以及簽訂包含價格保護條款的長期供應協議，實現供應鏈多元化，從而降低關稅和貿易政策的影響。

採用綜合臨床醫師訪談、技術性能評估、監管審查和通路經濟學的調查方法，建構了嚴謹的多面向分析。

該研究的綜合分析基於多學科調查方法，結合了臨床、技術、監管和商業性觀點。主要資訊來源包括對急診醫學和心臟病學臨床醫生、門診和醫院採購負責人以及診斷設備製造商和分銷合作夥伴的高管進行的結構化訪談，以深入了解推廣應用障礙和工作流程優先事項。次要資訊來源包括對同儕審查的科學文獻、監管指導文件以及近期發布的監管文件（詳細說明醫療設備核准、測試檢驗和互通性要求）的系統性回顧。此外，還進行了一項技術評估，將包括生物感測器、免疫檢測和橫向流動化驗在內的分析方法與臨床性能標準和可用性指標進行配對。

本文簡要概述了相關人員為充分發揮分散式心臟診斷的潛力而必須解決的臨床、技術和操作要求。

總之，心臟就地檢驗在現代心血管診療流程中發揮著至關重要的作用，能夠加快急診、門診和家庭環境中的臨床決策。高靈敏度檢測、生物感測器創新以及數位化整合技術的進步正在拓展其實際應用範圍，而報銷和法規環境的變化則影響其應用軌跡。然而，近期貿易政策的波動凸顯了供應鏈韌性、成本透明度和適應性籌資策略對於維持競爭優勢和確保診斷用品穩定供應的重要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 利用攜帶式照護現場分析儀進行高靈敏度肌鈣蛋白檢測法，快速診斷心肌梗塞
  • 智慧型手機連接的心電圖設備可實現遠端心律不整監測和心臟事件檢測。
  • 開發一種多重生物標記平台，能夠在緊急醫療環境中同時檢測心臟功能生物標記。
  • 將人工智慧演算法整合到就地檢驗設備中，以提高急性冠狀動脈症候群診斷的準確性
  • 實施雲端基礎的資料管理系統，實現醫療保健網路內心臟檢測結果的即時共用
  • 監管核准趨勢促進新型微流體心臟照護現場診斷晶片進入市場
  • 加強設備製造商與遠端醫療提供者之間的合作，以擴大農村地區心臟檢測的覆蓋範圍

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型就地檢驗市場

  • BNP
    • BNP
    • Nt ProBNP
  • C反應蛋白
    • 高敏C反應蛋白
    • 標準C反應蛋白
  • CK MB
  • 肌紅蛋白
  • 肌鈣蛋白
    • 肌鈣蛋白 I
    • 肌鈣蛋白T

9. 按最終用戶就地檢驗市場

  • 門診治療中心
  • 急診診所
  • 居家醫療
  • 醫院檢查室

第10章 按分銷管道就地檢驗市場

  • 醫院藥房
  • 線上管道
    • B2B入口網站
    • D2C
  • 零售藥房

第11章：依檢測模式就地檢驗市場

  • 定性
  • 定量

12. 依技術就地檢驗市場

  • 生物感測器
    • 電化學感測器
    • 光學感測器
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素免疫分析法
  • 橫向流動化驗

第13章：按應用就地檢驗市場

  • 心肌梗塞的診斷
  • 心臟衰竭監測
  • 風險評估

14. 各地區心臟就地檢驗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 按群體就地檢驗市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：各國心臟就地檢驗市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Abbott Laboratories
    • F. Hoffmann-La Roche AG
    • Siemens Healthineers AG
    • Quidel Corporation
    • Radiometer Medical ApS
    • Nova Biomedical Corporation
    • Sekisui Diagnostics, LLC
    • Accriva Diagnostics, Inc
    • Randox Laboratories Ltd
Product Code: MRR-3F5063247F53

The Cardiac Point of Care Testing Market is projected to grow by USD 25.95 billion at a CAGR of 13.55% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.38 billion
Estimated Year [2025] USD 10.66 billion
Forecast Year [2032] USD 25.95 billion
CAGR (%) 13.55%

A strategic framing of why accelerated diagnostic responsiveness and decentralized cardiac testing are reshaping clinical pathways and market priorities

Cardiac point-of-care testing has emerged as a critical inflection point for acute and chronic cardiovascular care pathways, enabling faster clinical decision-making at the patient's side and expanding diagnostic reach beyond traditional laboratory settings. Recent technological advances have reduced assay run-times and improved analytical sensitivity, while healthcare delivery trends have driven demand for decentralized testing in emergency clinics, ambulatory care centers, home healthcare settings, and hospital laboratories. These dynamics are reshaping how clinicians triage chest pain, monitor heart failure, and stratify cardiovascular risk, with faster diagnostic results translating into more timely interventions and streamlined care pathways.

Concurrently, improvements in immunoassay platforms, lateral flow devices, and biosensor technologies are converging with digital integration and connectivity solutions, enabling more actionable data flows and remote monitoring capabilities. This shift is accompanied by evolving reimbursement and regulatory frameworks that are increasingly accommodating point-of-care modalities, albeit with variability across regions. Therefore, stakeholders-ranging from device manufacturers and distributors to hospital procurement teams and policy makers-must weigh clinical utility, workflow integration, and cost structures when evaluating adoption strategies.

This introduction frames the subsequent analysis by emphasizing clinical impact, technological progress, and operational considerations that together define strategic opportunities and risks in cardiac point-of-care testing.

How advances in biomarker sensitivity, device miniaturization, and care delivery reforms are jointly redefining cardiac diagnostics and clinical workflows

The landscape of cardiac point-of-care testing is undergoing transformative shifts driven by a combination of technological innovation, clinical practice evolution, and healthcare delivery reform. High-sensitivity biomarker assays have extended the diagnostic window for myocardial injury and heart failure, prompting emergency and ambulatory settings to re-evaluate triage protocols and reduce time-to-treatment. At the same time, biosensor miniaturization and improvements in assay chemistry have made reliable quantitative results feasible outside central laboratories, supporting a broader shift toward decentralized, patient-centric diagnostics.

These technology-driven advances are intersecting with shifting care models, where hospital-at-home initiatives, urgent care expansions, and remote monitoring programs are increasing demand for portable, rapid testing. Payment models that reward value-based outcomes and shorter hospital stays further incentivize adoption of point-of-care solutions that can demonstrably reduce length of stay and improve therapeutic targeting. In parallel, digital health integration and interoperability standards are creating expectations for secure data exchange and seamless inclusion of point-of-care results into electronic health records and clinical decision support systems.

Finally, competitive dynamics are changing as established diagnostics companies invest in connectivity and user-experience design, while agile medtech entrants focus on platform flexibility and cost-effective manufacturing. Collectively, these shifts are redefining where and how cardiac biomarkers are measured, how results influence care, and which capabilities will determine market leadership in the near term.

Examining the operational and commercial consequences of 2025 tariff changes and how they compel supply chain resilience, sourcing shifts, and pricing strategies

The introduction of cumulative tariff measures in 2025 has created a new layer of commercial and operational complexity for the cardiac point-of-care testing ecosystem. Tariff-driven cost pressures on imported components, reagent raw materials, and finished diagnostic devices have prompted manufacturers and distributors to reassess sourcing strategies and supply chain architectures. Some organizations have accelerated supplier diversification efforts, prioritizing partners in lower-tariff jurisdictions or pursuing nearshoring options to mitigate exposure to trade policy volatility. These strategic responses have immediate procurement implications and may influence product pricing and margin dynamics across distribution channels.

In practice, increased import costs have been met with a range of adaptations, including longer-term supplier contracts with price-protection clauses, localized assembly to avoid duties on finished goods, and redesigns that reduce dependence on tariff-affected materials. For end users, particularly smaller ambulatory centers and retail pharmacy channels, the pass-through of higher unit costs can constrain adoption momentum unless offset by demonstrable clinical and operational value. Payers and health systems are responding by scrutinizing total cost of care impacts, requiring clearer evidence that point-of-care testing shortens workflows or avoids downstream expenses.

Regulatory and customs processing delays associated with tariff implementation have also highlighted the need for robust inventory planning and buffer strategies. Overall, the tariff environment has elevated supply chain resilience and cost transparency as strategic priorities for manufacturers, distributors, and health system purchasers alike.

Detailed segmentation analysis connecting product categories, end-user requirements, distribution routes, test modes, technologies, and clinical applications to unlock targeted strategic priorities

A granular segmentation analysis reveals where clinical demand, technology fit, and distribution dynamics intersect to create differentiated opportunities across the cardiac point-of-care testing landscape. Product type segmentation encompasses BNP, C Reactive Protein, CK MB, Myoglobin, and Troponin, with further granularity for BNP split into BNP and Nt ProBNP, C Reactive Protein divided into High Sensitivity and Standard assays, and Troponin distinguished between Troponin I and Troponin T. End user segmentation highlights distinct adoption patterns across ambulatory care centers, emergency clinics, home healthcare services, and hospital laboratories, each presenting unique workflow requirements, staffing competencies, and purchasing behaviours. Distribution channels reflect hospital pharmacies, online channels-including Business To Business portals and Direct To Consumer offerings-and retail pharmacies, each channel imposing different margin expectations and customer engagement models.

Test mode segmentation bifurcates the market into qualitative and quantitative modalities, a distinction that maps closely to clinical intent and regulatory scrutiny, while technology segmentation identifies biosensor, immunoassay, and lateral flow assay approaches, with biosensors further categorized into electrochemical and optical sensors and immunoassays differentiated into chemiluminescence immunoassay and enzyme linked immunosorbent assay formats. Application-based segmentation captures the primary clinical use cases of diagnosis of myocardial infarction, heart failure monitoring, and risk assessment, which dictate performance thresholds and integration needs.

Understanding these interlocking segments allows stakeholders to prioritize product development and go-to-market strategies that align analytic performance with user setting, distribution economics, and clinical value propositions, ensuring that innovations address the most pressing unmet needs across care settings.

How regional differences in healthcare infrastructure, regulatory expectations, and manufacturing ecosystems shape adoption pathways and strategic market entry approaches

Regional dynamics exert a material influence on adoption pathways, regulatory expectations, and supply chain decisions within cardiac point-of-care testing. In the Americas, clinical adoption is driven by emergency department demand for rapid triage and by expanding home-based care initiatives that favour portable diagnostics, while procurement cycles and reimbursement mechanisms vary widely between public and private systems. Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with market fragmentation, leading to differentiated pathways for devices and assays; in some areas, centralized systems remain dominant, whereas other markets show rapid uptake of decentralised testing, often influenced by public health priorities and investment capacity. Asia-Pacific displays a mix of advanced urban healthcare systems with sophisticated laboratory networks and rapidly expanding primary care infrastructures in emerging economies; this region's manufacturing capabilities and supplier ecosystems also play a central role in global supply chains, affecting sourcing decisions and price dynamics.

Each region imposes distinct requirements for clinical validation, quality systems, and distribution partnerships. For manufacturers and distributors, tailoring market entry strategies to these regional specifics-balancing regulatory timelines, channel selection, and local partnerships-will drive market traction. For healthcare providers and payers, regional context determines how point-of-care testing is prioritized within broader cardiovascular care initiatives and how value is assessed against competing clinical investments.

Competitive and partnership dynamics highlighting how platform incumbents and innovators leverage distribution, connectivity, and evidence generation to secure durable market positions

Competitive dynamics in cardiac point-of-care testing are shaped by a mix of established diagnostics manufacturers and agile innovators focusing on niche capabilities such as ultra-sensitive biomarkers, user-centric device design, and integrated digital ecosystems. Large-platform companies often leverage broad distribution networks, established regulatory footprints, and cross-portfolio synergies to scale introductions, while emerging entrants concentrate on platform flexibility, lower-cost manufacturing, or novel biosensor technologies that can be rapidly iterated.

Partnerships and strategic alliances are increasingly common as device developers seek to integrate assay expertise with connectivity providers and sample-to-result automation specialists. This collaborative approach accelerates time-to-market for features that matter to clinicians, such as real-time data transmission to electronic health records and decision-support compatibility. In addition, strategic licensing and OEM arrangements enable companies with strong commercial channels to offer complementary assays under co-branded or private-label models, expanding reach without duplicative infrastructure investments.

From a procurement perspective, health systems prioritize vendors that can demonstrate consistent supply, regulatory compliance, and clear pathways for technical support and training. Companies that invest in post-sales support models, local technical presence, and outcome-oriented evidence generation are best positioned to win durable contracts and to support broader clinical adoption across care settings.

Practical and prioritized actions for manufacturers, distributors, and health systems to accelerate adoption, enhance resilience, and align offerings with clinical priorities

Industry leaders seeking to accelerate adoption and build resilient operations should prioritize a set of actionable strategies that balance clinical credibility, supply chain agility, and end-user experience. First, invest in clinical evidence that links point-of-care testing to measurable improvements in patient pathways, such as reduced time-to-decision or avoidance of unnecessary admissions, and ensure that this evidence addresses different end-user contexts including ambulatory centers, emergency clinics, home healthcare, and hospital laboratories. Second, diversify supply chains to mitigate tariff and trade-policy exposure by developing alternate sourcing options, nearshoring assembly where feasible, and negotiating longer-term supply agreements with price protection.

Third, design product portfolios and distribution approaches tailored to channel economics; hospital pharmacies, online channels including B2B portals and direct-to-consumer routes, and retail pharmacies each require distinct pricing, packaging, and service propositions. Fourth, prioritize interoperability and digital integration so that point-of-care results feed seamlessly into clinical workflows and electronic records, thereby increasing clinical utility and adoption. Fifth, adopt a segmented go-to-market strategy that aligns technologies-whether biosensors, immunoassays, or lateral flow formats-with the specific performance requirements of applications such as myocardial infarction diagnosis, heart failure monitoring, and risk assessment.

By combining robust clinical evidence, supply chain resilience, channel-specific commercial design, digital enablement, and targeted segmentation, industry leaders can create defensible positions and accelerate sustainable uptake of cardiac point-of-care testing solutions.

Methodological approach integrating clinician interviews, technical performance assessments, regulatory reviews, and channel economics to build a rigorous multi-perspective analysis

This research synthesis draws on a multidisciplinary methodology designed to integrate clinical, technological, regulatory, and commercial perspectives. Primary inputs included structured interviews with clinicians in emergency medicine and cardiology, procurement professionals across ambulatory and hospital settings, and executives from diagnostic companies and distribution partners, providing qualitative insight into adoption barriers and workflow priorities. Secondary inputs comprised a systematic review of peer-reviewed scientific literature, regulatory guidance documents, and recent public filings that detail device clearances, assay validations, and interoperability requirements. Additionally, technology assessments were conducted to compare analytical approaches such as biosensors, immunoassays, and lateral flow assays against clinical performance criteria and usability metrics.

Analytical frameworks incorporated segmentation mapping to relate product types and technologies to end-user needs and distribution economics, along with scenario analysis to evaluate operational responses to external pressures such as tariff changes. Care was taken to ensure source triangulation, cross-validating claims from interviews with published validation studies and regulatory documentation. Limitations of the methodology include variable transparency in proprietary supplier cost structures and the evolving nature of trade policy and reimbursement pathways, which may influence implementation timelines. Nonetheless, the approach provides a rigorous basis for strategic decision-making by combining clinician perspectives, technical performance evaluation, and commercial channel analysis.

A concise synthesis of clinical, technological, and operational imperatives that stakeholders must align to realize the full potential of decentralized cardiac diagnostics

In conclusion, cardiac point-of-care testing occupies a pivotal role in modern cardiovascular care pathways, offering the potential to accelerate clinical decision-making across emergency, ambulatory, and home-based settings. The convergence of high-sensitivity assays, biosensor innovations, and improved digital integration is expanding the range of viable use cases, while evolving reimbursement and regulatory contexts are shaping adoption trajectories. However, recent trade-policy shifts underline the importance of supply chain resilience, cost transparency, and adaptive sourcing strategies to maintain competitive positioning and ensure consistent access to diagnostic supplies.

For stakeholders, the imperative is clear: align product performance with specific clinical workflows, demonstrate measurable impacts on patient management, and design distribution and support models that reflect the economic realities of each end-user segment. Companies that combine robust clinical evidence, flexible manufacturing and sourcing approaches, and strong post-sales support will be best positioned to convert technical promise into sustained clinical and commercial success. Moving forward, continued collaboration among manufacturers, clinicians, payers, and regulators will be essential to realize the full potential of decentralized cardiac diagnostics while maintaining quality, affordability, and equitable access.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of high-sensitivity troponin assays in handheld point of care analyzers for faster myocardial infarction diagnosis
  • 5.2. Emergence of smartphone-connected electrocardiogram devices enabling remote arrhythmia monitoring and cardiac event detection
  • 5.3. Development of multiplexed biomarker platforms for simultaneous detection of cardiac biomarkers in emergency settings
  • 5.4. Integration of artificial intelligence algorithms in point of care testing devices to improve diagnostic accuracy for acute coronary syndromes
  • 5.5. Implementation of cloud-based data management systems for real-time sharing of cardiac test results across healthcare networks
  • 5.6. Regulatory approval shifts driving market entry of novel microfluidic cardiac point of care diagnostic chips
  • 5.7. Increasing partnerships between device manufacturers and telehealth providers to expand cardiac testing accessibility in rural areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cardiac Point of Care Testing Market, by Product Type

  • 8.1. BNP
    • 8.1.1. BNP
    • 8.1.2. Nt ProBNP
  • 8.2. C Reactive Protein
    • 8.2.1. High Sensitivity C Reactive Protein
    • 8.2.2. Standard C Reactive Protein
  • 8.3. CK MB
  • 8.4. Myoglobin
  • 8.5. Troponin
    • 8.5.1. Troponin I
    • 8.5.2. Troponin T

9. Cardiac Point of Care Testing Market, by End User

  • 9.1. Ambulatory Care Centers
  • 9.2. Emergency Clinics
  • 9.3. Home Healthcare
  • 9.4. Hospital Laboratories

10. Cardiac Point of Care Testing Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Channels
    • 10.2.1. Business To Business Portals
    • 10.2.2. Direct To Consumer
  • 10.3. Retail Pharmacies

11. Cardiac Point of Care Testing Market, by Test Mode

  • 11.1. Qualitative
  • 11.2. Quantitative

12. Cardiac Point of Care Testing Market, by Technology

  • 12.1. Biosensor
    • 12.1.1. Electrochemical Sensor
    • 12.1.2. Optical Sensor
  • 12.2. Immunoassay
    • 12.2.1. Chemiluminescence Immunoassay
    • 12.2.2. Enzyme Linked Immunosorbent Assay
  • 12.3. Lateral Flow Assay

13. Cardiac Point of Care Testing Market, by Application

  • 13.1. Diagnosis Of Myocardial Infarction
  • 13.2. Heart Failure Monitoring
  • 13.3. Risk Assessment

14. Cardiac Point of Care Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cardiac Point of Care Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cardiac Point of Care Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Abbott Laboratories
    • 17.3.2. F. Hoffmann-La Roche AG
    • 17.3.3. Siemens Healthineers AG
    • 17.3.4. Quidel Corporation
    • 17.3.5. Radiometer Medical ApS
    • 17.3.6. Nova Biomedical Corporation
    • 17.3.7. Sekisui Diagnostics, LLC
    • 17.3.8. Accriva Diagnostics, Inc
    • 17.3.9. Randox Laboratories Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NT PROBNP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HIGH SENSITIVITY C REACTIVE PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STANDARD C REACTIVE PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK MB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BUSINESS TO BUSINESS PORTALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIRECT TO CONSUMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUALITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY QUANTITATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ELECTROCHEMICAL SENSOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY OPTICAL SENSOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSIS OF MYOCARDIAL INFARCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART FAILURE MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RISK ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BNP, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY C REACTIVE PROTEIN, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ONLINE CHANNELS, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY TEST MODE, 2018-2024 (U